Take­da kicks off JPM week with M&A — buy­ing out an­oth­er gam­ma/delta spin­out and div­ing in­to a new ‘swim lane’

Less than 3 months af­ter Take­da scooped up Gam­maDelta in a bid to ex­pand its work on next-gen cell ther­a­pies, the phar­ma gi­ant is back — start­ing off JP Mor­gan week with an­oth­er ac­qui­si­tion in the field.

This time, the buy­out tar­get is Adap­tate Bio­ther­a­peu­tics and its pre­clin­i­cal work on an an­ti­body-based γδ T cell en­gager plat­form, a spin­out from Gam­maDelta that Take­da be­lieves gives them a shot at lead­ing the pack in cell ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER